PMID- 20231816
OWN - NLM
STAT- MEDLINE
DCOM- 20120202
LR  - 20100316
IS  - 2589-0646 (Electronic)
IS  - 2589-0646 (Linking)
VI  - 3
IP  - 1
DP  - 2010
TI  - Gibbon ape leukemia virus transduction of peripheral blood CD34+-derived 
      dendritic cells.
PG  - 399-402
AB  - BACKGROUND: Dendritic cells (DCs) play a critical role in the immune response and 
      are a candidate for immunotherapy in cancer. Since gibbon ape leukemia virus 
      (GALV) transduction of CD34+ cells is reasonably efficacious, we assessed the 
      efficacy of GALV transduction of CD34+ derived DCs as a possible approach to 
      creating genetically modified DCs for immunotherapy. METHODS: Peripheral blood 
      CD34+ cells were transduced with retroviruses obtained from the PG13/LN C8 cell 
      line, with the neomycin gene as a marker gene. After prestimulation of 
      hematopoietic cells for 24 hours with 10 ng/mL interleukin (IL)-3, 10 ng/mL IL-6, 
      100 ng/mL stem cell factor, 100 ng/mL granulocyte-macrophage colony stimulating 
      factor and 8 Amicrog/mL protamine sulfate, the cells were cultured in a 
      transforming media prior to differentiating into DCs by GM-CSF, TNF-a and IL-4. 
      Immunophenotyping analyses for confirmation of the generated DCs, colony 
      formation assay and PCR were done for the expression of neomycin gene in the 
      transduced cells. RESULTS: Titration of viral vectors indicated a transduction 
      efficiency of 1x10(5) CFU/mL. Transduction efficiency for the CD34+ cells 
      transformed to DCs was 45% and 38% before and after DC differentiation, 
      respectively. Additionally, a mean (SEM) of 26.9% (11.4%) and 41.4% (11.8%) of 
      the genetically modified DCs were positive for CD86+ HLA-DR and CD1a+CD14, 
      respectively CONCLUSION: This study showed that the majority of transduced CD34+ 
      cells were successfully differentiated into cells identical to DCs according to 
      morphology and immunophenotyping features, which could be a potential application 
      in immunotherapy.
FAU - Moezzi, Leili
AU  - Moezzi L
AD  - Faculty of Paramedical Sciences, Tehran University of Medical Sciences, Tehran, 
      Iran.
FAU - Alimoghaddam, Kamran
AU  - Alimoghaddam K
FAU - Saleh, Alireza J
AU  - Saleh AJ
FAU - Shahrokhi, Somayeh
AU  - Shahrokhi S
FAU - Ghaffari, Seyes Hamidolah
AU  - Ghaffari SH
FAU - Bagheri, Nadia
AU  - Bagheri N
FAU - Chardouli, Bahram
AU  - Chardouli B
FAU - Ghavamzadeh, Ardeshir
AU  - Ghavamzadeh A
LA  - eng
PT  - Journal Article
PL  - Saudi Arabia
TA  - Hematol Oncol Stem Cell Ther
JT  - Hematology/oncology and stem cell therapy
JID - 101468532
RN  - 0 (Antigens, CD34)
SB  - IM
MH  - *Antigens, CD34
MH  - Blood Cells
MH  - Cell Culture Techniques/methods
MH  - Cell Differentiation
MH  - Dendritic Cells/cytology/*metabolism
MH  - Hematopoietic Stem Cells/cytology
MH  - Humans
MH  - Immunotherapy/*methods
MH  - Leukemia Virus, Gibbon Ape/*genetics
MH  - Transduction, Genetic/*methods
EDAT- 2010/03/17 06:00
MHDA- 2012/02/03 06:00
CRDT- 2010/03/17 06:00
PHST- 2010/03/17 06:00 [entrez]
PHST- 2010/03/17 06:00 [pubmed]
PHST- 2012/02/03 06:00 [medline]
AID - 10-019 [pii]
PST - ppublish
SO  - Hematol Oncol Stem Cell Ther. 2010;3(1):399-402.